Edition:
India

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

3.43USD
17 Nov 2017
Change (% chg)

$-0.10 (-2.83%)
Prev Close
$3.53
Open
$4.00
Day's High
$4.00
Day's Low
$3.35
Volume
38,695
Avg. Vol
23,764
52-wk High
$6.43
52-wk Low
$2.45

Summary

Name Age Since Current Position

Xiaochun Xu

45 2017 Chairman of the Board, President, Chief Executive Officer

Jeffery Cauble

2017 Principal Financial Officer, Principal Accounting Officer

Venkatesh Ponemone

40 Executive Director of India Operations, Director of Clinical and Scientific Affairs

Vivian Liu

2017 Chief Operating Officer

Kimberly Ellner

49 2016 Vice President of Manufacturing and Global Supply Chain

Russell Medford

57 2017 Director

Joseph Thomis

2017 Director

James Xu

2016 Director

Mahendra Rao

55 2014 Independent Director

Denis Rhein

56 2014 Independent Director

Biographies

Name Description

Xiaochun Xu

Dr. Xiaochun Xu is Chairman of the Board, President, Chief Executive Officer of the Company. He is the Founder, Chairman and CEO of Boyalife Group. He received his Ph.D. degree in Immunology from Washington University School of Medicine (St. Louis, USA) and an Executive MBA degree from Emory University (Atlanta, USA). Dr. Xu has over 15 years of managerial experience in biomedicine and the pharmaceutical industry and has been involved in the discovery and development of several blockbuster drugs. Since 2000 he served as a Project Leader at Pfizer, as a Director of Research at two publicly-traded companies and as a Vice President at Founder Group. He has authored over 40 publications and won several international awards from various professional societies for excellence in biomedical research.

Jeffery Cauble

Mr. Jeff Cauble has been appointed as Principal Financial Officer, Principal Accounting Officer of the Company, effective March 10, 2017. Mr. Cauble has been employed with the Company since 2010 and has served as Accounting Manager, Assistant Controller and Director of Finance. Mr. Cauble has over 19 years of accounting experience in various financial and managerial roles for Diamond Foods Inc. (DMND) and E.&J. Gallo Winery. Mr. Cauble is a Certified Public Accountant and graduated from University of Idaho with a BS in accounting and finance.

Venkatesh Ponemone

Dr. Venkatesh Ponemone is a Executive Director of India Operations, Director of Clinical and Scientific Affairs of the Company. He has served as the Executive Director of Indian operations and Director for Clinical Affairs and GMP Laboratory since September 2008. Prior to joining TotipotentRX, now a wholly owned subsidiary of Cesca Therapeutics Inc, he was an Assistant Professor of Medical Microbiology at Kamineni Graduate School of Medicine, Hyderabad, India. Dr. Ponemone completed a two year post-doctoral position in the arena of inflammatory disease and immunology at the University of Illinois, Chicago, and has authored more than 35 peer reviewed publications on regenerative medicine, the role of cytokines in autoimmune disease, and radioprotective and chemoprotective agents in cancer treatment. Dr. Ponemone is a Fellow of Academic General Education, has a Ph.D. from Manipal University in radiation therapy and oncology, holds a post-graduate degree in Medical Microbiology from Kasturba Medical College, Manipal University and holds a Masters degree in Business Administration degree from Sikkim Manipal University.

Vivian Liu

Ms. Vivian Liu serves as Chief Operating Officer, Director of the Company. Ms. Liu is currently a partner at OxOnc Development LP, and also a member of the board of directors at Innovus Pharmaceuticals, Inc. where she previously served as president and chief executive officer. Ms. Liu co-founded Apricus Biosciences, Inc., a NASDAQ traded company, and served in numerous capacities, including chairman of the board, chief executive officer and chief financial officer. Ms. Liu received her B.A. in International Relations from University of California, Berkeley in 1983 and her MPA in International Finance from University of Southern California in 1985.

Kimberly Ellner

Ms. Kimberly Ellner is a Vice President of Manufacturing and Global Supply Chain of the Company. She was appointed Vice President of Manufacturing and Global Supply Chain in March 2016. Since joining the company in 2003, Ms. Ellner has held various positions in Operations including Sr. Director of Global Supply Chain and Sr. Director of Operations where Ms. Ellner has managed the production, procurement, logistics, customer support, and manufacturing engineering functions. Ms. Ellner has over 25 years of experience in various medical device operational roles. Prior to joining Cesca, Ms. Ellner worked for Oratech Interventions, Inc., now Smith and Nephew, where Ms. Ellner held the positions of Materials Manager, Manufacturing Finance Manager, and Business Process Improvement Manager. She also worked for Stryker Corporation in the Instruments and Endoscopy divisions holding positions of Production Supervisor, Business Unit Manager and Materials Manager. Ms. Ellner graduated with honors from Western Michigan University with a Bachelor of Science degree in Manufacturing Administration.

Russell Medford

Dr. Russell M. Medford, M.D., Ph.D., has been appointed as Director of the Company., effective February 24, 2017. Dr. Medford has been a Managing Partner of the Salutramed Group, LLC since 2012. Dr. Medford has served as the Chief Executive Officer of healthEgames, Inc., a digital healthcare company and as the Chairman of ViaMune, Inc. since 2014. From 1993 to 2009, Dr. Medford served as co-founder, President, CEO and Director of AtheroGenics, Inc (AGIX). He was a founding Board Director of Inhibitex, Inc. (INHX) until it was acquired by Bristol-Myers-Squibb in 2012. Dr. Medford is a board-certified physician, and currently holds numerous trustee or board positions including Georgia Global Health Alliance, Inc., and Georgia BIO (previously Georgia Biomedical Partnership). Dr. Medford obtained his MD and PhD from the Albert Einstein College of Medicine.

Joseph Thomis

Dr. Joseph Thomis is Director of the company. He received his PH.D. in Pharmaceutical Sciences from the University of Leuven in Belgium. Dr. Thomis did a Postdoctoral Fellowship in Pharmacology at the University of Leuven and Postdoctoral work in Cardiac Cellular and Human Cardiac Electrophysiology at St. Jozef’s Clinic Ostende, Belgium. For over four decades, Dr. Thomis has been involved in the clinical and commercial development of new medicines. Since 2012 he has been the Chief Executive Officer at Thomis Consulting bvba and a partner in OxOnc, a virtual clinical development company. From 1997-2012 he was at Quintiles Transnational where he held numerous positions including Chairman of the American Management Board President of Global Clinical Development Services and President of European Clinical Development Services. From 1976-1996 he was at Bristol-Myers Squibb serving in various Assistant Director and Director positions. Dr. Thomis has served as a non-executive director at NovaQuest LLC, a private equity company since 2014 and Chairman of the Board of Quotient Clinical, a translational pharmaceutics company since 2016. From 2012 to 2013 he was a non-executive director of PDP Courier Services, Ltd and from 2010-2012 he was Chairman of the American Management Board of Quintiles.

James Xu

Mr. James Xu serves as Director of the Company. Mr. Xu is a practicing attorney and licensed CPA in the State of Illinois with over 18 years of experience in corporate operation strategy and litigation, including patent prosecution and litigation, intellectual property licensing, corporate strategic taxation planning, corporate restructuring and mergers and acquisitions. Mr. Xu has been the General Counsel of the Boyalife Group since 2010. He received an M.S. in Electrical Engineering and an MBA from the University of Mississippi a J.D. and LL.M. in Taxation from DePaul Law School, and an LL.M. in Intellectual Properties and an LL.M. in Information Technologies from John Marshall Law School. Mr. James Xu is also licensed by the U.S. Patent and Trademark Office.

Mahendra Rao

Dr. Mahendra S. Rao, Ph.D., is an Independent Director of Cesca Therapeutics Inc., since April 1, 2014. Dr. Rao has been engaged as a consultant with his own consulting firm Mahendra Rao, LLC. Dr. Rao was the Director and Chief of Laboratory of Stem Cell Biology at the National Institute of Health (NIH) from 2011 through 2014. Dr. Rao was Vice President, Regenerative Medicine at Life Technologies Inc. (now Thermo Fisher Scientific) from 2006 through 2011. From May 2001 through October 2005 Dr. Rao was Stem Cell Section Chief and Senior Investigator at the National Institute on Aging’s Laboratory of Neuroscience. Dr. Rao has also held associate professor positions at both the Johns Hopkins University and the University of Utah Schools of Medicine. Dr. Rao is the scientific co-founder, Chief Strategy Officer and Chairman of the Scientific Advisory Board of Q Therapeutics, a company working on the development of cellular therapy to treat central nervous system diseases. He holds degrees from Bombay University in India and earned his Ph.D. in developmental neurobiology from California Institute of Technology.

Denis Rhein

Mr. Denis Michael Rhein is an Independent Director of Cesca Therapeutics Inc., since December 2014. Mr. Rhein has over 30 years of corporate banking and securities experience at Deutsche Bank AG in Frankfurt, Germany, where he served in various executive management positions including Managing Director in Corporate and Investment Banking and in Wealth Management, Global Head of Hedge Fund Research, Head of Alternative Investments, and Head of Product Development. Mr. Rhein retired from Deutsche Bank in June 2013. Mr. Rhein is the founder and a Director of EMR Vermögensverwaltung GmbH, an investment management company, since July 2013. He is also founder, Principal Shareholder and a Director of Illumisound GmbH, an energy efficient commercial lighting company, since October 2013. Mr. Rhein was a director of TotipotentRX Corporation from 2012 until the merger that resulted in the formation of Cesca Therapeutics in February 2014. Mr. Rhein is one of our independent directors.

Basic Compensation